Concepedia

A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

Stuart L. Emanuel, Robert H. Gruninger, Angel R. Fuentes‐Pesquera, Peter J. Connolly, Jennifer A. Seamon, Susan Hazel, Rose Tominovich, Beth Hollister, Cheryl Napier, Michael R. D’Andrea,

Molecular Pharmacology · 2004 · 41 citations · 41 references

DOI

Concepts

References

41

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

K. Jin Kim, Bing Li, Jane Winer et al. · Nature · 1993 · 3.6K citations

, , +14

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry et al. · New England Journal of Medicine · 2003 · 2.7K citations · Full text

, , +17

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

B Millauer, Susanne Wizigmann-Voos, Harald Schnürch et al. · Cell · 1993 · 1.9K citations

, , +16

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

Fairooz F. Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2002 · 1.7K citations

, , +13

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

Thomas Boehm, Judah Folkman, Timothy Browder et al. · Nature · 1997 · 1.7K citations

, , +16